Kevin McCulloch files SEC Form 4 disclosures for Xeris Biopharma Holdings, Inc.. They have made 1 open-market trade across 1 company since 2025, most recently 2026-10-01.
CIK 0002031695
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $110K since 2025, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XERS | 1,599,208 | $16.5M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XERS | SELL · 10b5-1 | 2026-10-01 | 2026-10-02 | $9.41 | $141K | +7.1% | — | — |
| XERS | SELL · 10b5-1 | 2026-09-28 | 2026-09-29 | $10.00 | $250K | +4.9% | — | — |
| XERS | SELL · 10b5-1 | 2026-09-01 | 2026-09-01 | $8.49 | $127K | -11.6% | +7.9% | — |
| XERS | SELL · 10b5-1 | 2026-08-03 | 2026-08-04 | $8.02 | $120K | +4.1% | +4.0% | — |
| XERS | SELL · 10b5-1 | 2026-07-01 | 2026-07-02 | $8.03 | $723K | +4.7% | -2.1% | +15.0% |
| XERS | SELL · 10b5-1 | 2026-01-08 | 2026-01-09 | $8.00 | $120K | -3.3% | -11.6% | -23.6% |
| XERS | BUY | 2025-06-13 | 2025-06-16 | $4.38 | $110K | +4.9% | +17.4% | +64.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.